Recently published studies have demonstrated new developments in Barrett’s esophagus and achalasia.
In case you missed it, the editors of Healio Gastroenterology and Liver Disease have compiled a recap of some of our most recent popular articles involving esophagus-related diseases.
Traction-assisted ESD reduces procedure time in patients with large esophageal cancers
Endoscopic submucosal dissection with traction assistance helped reduce procedure time and avoid adverse events in patients with large esophageal cancers, according to study results.
In traction-assisted endoscopic submucosal dissection (TA-ESD), the endoscopist pulls the lesion in the oral direction, which allows for tangential visualization of the dissection line, reducing the risk for technical difficulties. READ MORE.
Esophageal symptom burden in obesity tied to reflux
Esophageal symptoms in patients with obesity are caused by gastroesophageal reflux and not dysmotility, according to study results.
“Despite reports of increased prevalence of abnormal manometric diagnoses and esophageal reflux burden in obese individuals, relationships between esophageal symptom burden and objective data from esophageal testing remain incompletely understood,” C. Prakash Gyawali, MD, of the division of gastroenterology at Washington University School of Medicine in St. Louis, and colleagues wrote. “In this retrospective, observational cohort study of consecutive patients referred for esophageal testing, we sought to evaluate relationships between BMI and esophageal symptom burden, [esophageal motor disorders] according to Chicago Classification and esophageal reflux burden.” READ MORE.
Barrett’s with indefinite for dysplasia carries risk for progression
Patients with Barrett’s esophagus with indefinite for dysplasia are at similar risk for malignant progression and should be screened like patients with low-grade dysplasia, according to results of a meta-analysis published in Gastrointestinal Endoscopy.
“Currently, there are no reliable estimates for progression risk to [high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC)] in patients with [Barrett’s esophagus with indefinite for dysplasia (BE-IND)],” Prasad G. Iyer, MD, MSc, from the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota, and colleagues wrote. “Hence, management strategies for BE-IND are unclear and endoscopy is not routinely recommended.” READ MORE.
Novel therapy shows potential for acid suppression
Tegoprazan, a novel therapy for GERD, was well tolerated and showed rapid, dose-dependent acid suppression, according to results of a phase 1 study.
Kyun-Seop Bae, MD, PhD, of the department of clinical pharmacology and therapeutics at the University of Ulsan in South Korea, and colleagues wrote that tegoprazan (CJ HealthCare) is a potassium-competitive acid blocker (P-CAB) that works by reversibly suppressing gastric H+/K+ATPase. READ MORE.
Anterior, posterior POEM both effective achalasia treatments
Using either posterior or anterior myotomy during peroral endoscopic myotomy can provide clinical success in the treatment of achalasia, according to study results.
Mouen A. Khashab, MD, from the division of gastroenterology and hepatology at Johns Hopkins Medical Institutions, and colleagues wrote that while finding the optimal clinical approach to peroral endoscopic myotomy (POEM) is crucial, data comparing these techniques are limited. READ MORE.